Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01290367 | Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain | PHASE2 | COMPLETED | 100 | — | — | Aug 1, 2011 | Jul 1, 2015 | Jun 26, 2020 | 14 | United States, Australia |
| Arm | Type | Description |
|---|---|---|
| High Dose MPCs | EXPERIMENTAL | Injection of High Dose MPCs with Hyaluronic Acid |
| Low Dose MPCs | EXPERIMENTAL | Injection of Low Dose MPCs with Hyaluronic Acid |
| Saline injection | SHAM_COMPARATOR | Injection of saline solution. |
| Hyaluronic acid injection | PLACEBO_COMPARATOR | Injection of hyaluronic acid solution |
| Name | Type | Description |
|---|---|---|
| Single Dose MPCs Injection | BIOLOGICAL | Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus. |
| Single injection of saline solution | PROCEDURE | Intradiscal control injection with saline solution |
| Single injection of hyaluronic acid | PROCEDURE | Intradiscal control injection with hyaluronic acid |
Inclusion Criteria: 1. Male or females at least 18 years of age. 2. Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol. 3. Have the ability to understand and provide written authorization for the use and disclosur...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mesoblast Limited Sponsored ADR | MESO | 1 | PHASE3 | Rexlemestrocel-L + HA mixture, Saline |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
| Stryker Corporation | SYK | 2 | NA | Undisclosed |
| Globus Medical Inc Class A | GMED | 6 | — | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | — | Undisclosed |